Investors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class Action - ATNM

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Summary by Sections Class Action Details - The lawsuit aims to recover losses for investors who were misled by false statements regarding the company's Phase 3 Sierra trial data and its implications for the FDA approval of the targeted radiotherapy, Iomab-B BLA [2]. - Allegations include that the data from the Sierra trial was unlikely to meet FDA guidelines, and additional analyses provided to the FDA were also unlikely to satisfy approval requirements [2]. Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].